亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

The Integrin Activation Interface

技術優勢

Can be used with high specificity to modulate the talin-integrin beta-sub3 interaction without the side effects that may occur with presently available therapeutic agents and methods. Offers a new screening method to detect agents that block integrin beta-sub3 activation, as well as a method for screening alterations in talin function. Available as DNA constructs and vectors.

詳細技術說明

Researchers at UC San Diego have elucidated a novel molecular interface between two proteins, talin and the membrane proximal portion of the beta-sub3 integrin domain. Specifically, the research team has identified and validated a specific structural target that was previously unknown and could aid in the design of therapeutics to block integrin activation. This discovery may enable the engineering of cells with defects in the activation of multiple classes of integrins and offers a new target for therapeutic intervention to treat diseases and conditions such as inflammation, autoimmune diseases, heart disease (including myocardial infarction), and cancer.

附加資料

Patent Number: US8530621B2
Application Number: US2009523037A
Inventor: Ginsberg, Mark | Partridge, Anthony William | Campbell, Iain | Wegener, Kate Louise
Priority Date: 12 Jan 2007
Priority Number: US8530621B2
Application Date: 26 Apr 2010
Publication Date: 10 Sep 2013
IPC Current: A61K003804
US Class: 530324
Assignee Applicant: The Regents of the University of California
Title: Combined preparation of a thiazide diuretic and a loop diuretic
Usefulness: Combined preparation of a thiazide diuretic and a loop diuretic
Summary: The isolated complex is useful for blocking integrin β 3 activation for treating a condition or disease e.g. myocardial infarction, tumor metastasis, and rheumatoid arthritis; and for screening to detect an agent that blocks integrin β 3 activation (all claimed). It is also useful for screening for alteration in talin function.
Novelty: New isolated complex comprising a structural interface between talin and integrin beta-3, useful for blocking integrin beta-3 activation for treating a condition e.g. myocardial infarction, tumor metastasis, and rheumatoid arthritis